Rely on PPD’s experienced infectious diseases team to deliver the optimal clinical strategy. As new markets are identified for conducting clinical research, our team is already on the ground and well-prepared to start trials quickly and keep them on track. PPD has conducted more than 200 protocols in infectious diseases indications involving more than 9,000 sites and 230,000 patients over the past five years.1
PPD’s experienced infectious diseases team:
- Offers reliable access to patients worldwide
- Applies deep therapeutic experience and global resources to streamline the development process from clinical through post-approval
- Uses our global network of monitors, project managers, regulatory specialists, data managers, biostatisticians, medical writers, lab technicians, scientists and medical professionals to ensure rapid, efficient execution of clinical trials
Infectious Diseases Global Investigator Network
PPD’s robust global investigator database includes more than 2,200 adult and pediatric infectious diseases specialists in 59 countries in various specialties, including HIV, hepatitis C, parasitic diseases and medical microbiology. With experience in a broad range of infectious diseases indications, these investigators provide access to specialized clinical sites with proven trial experience.
Microbiology Laboratory Services
PPD's central laboratories support clinical trials worldwide in infectious diseases drug development through our laboratory testing services and expanded capabilities in our clinical microbiology laboratories.
PPD offers clients:
- A full range of microbiology testing services, such as bacteriology, mycobacteriology and testing of microbioterrorism pathogens
- Extensive virology testing, including real-time polymerase chain reaction, viral load, genotyping and single nucleotide polymorphism analysis
- The capability to culture, quantitate, identify and determine antibiotic susceptibility and resistance for aerobic and anaerobic organisms
- A flexible approach to microbiology testing, performing disk diffusion and/or broth dilution assays to establish antibiotic minimum inhibitory concentration and breakpoints
1. These numbers do not include our work in the government and public health services sector, which is managed separately.